Next-Generation Immunotherapy: Advancing Clinical Applications in Cancer Treatment
Journal of Clinical Medicine · 30.10.2024 · 13 (21) · 6537
DOI: 10.3390/jcm13216537 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 30.10.2024. Verfasst von Pankaj Garg und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, GLA University, Mathura 281406, Uttar Pradesh, India. Die Arbeit wurde bisher 124-mal zitiert (Crossref) und nennt 100 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: United States Department of Defense, The National Cancer Institute of the National Institutes of Health, City of Hope’s Beckman Research Institute.
Abstract (Originalsprache)
Next-generation immunotherapies have revolutionized cancer treatment, offering hope for patients with hard-to-treat tumors. This review focuses on the clinical applications and advancements of key immune-based therapies, including immune checkpoint inhibitors, CAR-T cell therapy, and new cancer vaccines designed to harness the immune system to combat malignancies. A prime example is the success of pembrolizumab in the treatment of advanced melanoma, underscoring the transformative impact of these therapies. Combination treatments, integrating immunotherapy with chemotherapy, radiation, and targeted therapies, are demonstrating synergistic benefits and improving patient outcomes. This review also explores the evolving role of personalized immunotherapy, guided by biomarkers, genomic data, and the tumor environment, to better target individual tumors. Although significant progress has been made, challenges such as resistance, side effects, and high treatment costs persist. Technological innovations, including nanotechnology and artificial intelligence, are explored as future enablers of these therapies. The review evaluates key clinical trials, breakthroughs, and the emerging immune-modulating agents and advanced delivery systems that hold great promise for enhancing treatment efficacy, reducing toxicity, and expanding access to immunotherapy. In conclusion, this review highlights the ongoing advancements in immunotherapy that are reshaping cancer care, with future strategies poised to overcome current challenges and further extend therapeutic reach.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Chemistry, GLA University, Mathura 281406, Uttar Pradesh, India.
- Departments of Medical Oncology & Therapeutics Research, Beckman Research Institute of City of Hope, Comprehensive Cancer Center and National Medical Center, Duarte, CA 91010, USA.
- Departments of Molecular Medicine, Beckman Research Institute of City of Hope, Comprehensive Cancer Center and National Medical Center, Duarte, CA 91010, USA.
ORCID-Profile: Ravi Salgia
Förderung
- United States Department of Defense
- The National Cancer Institute of the National Institutes of Health
- City of Hope’s Beckman Research Institute
Zitieren
APA
Garg, P., Pareek, S., Kulkarni, P., Horne, D., Salgia, R., & Singhal, S. S. (2024). Next-Generation Immunotherapy: Advancing Clinical Applications in Cancer Treatment. Journal of Clinical Medicine, 13(21), 6537. https://doi.org/10.3390/jcm13216537
Vancouver
Garg P, Pareek S, Kulkarni P, Horne D, Salgia R, Singhal SS. Next-Generation Immunotherapy: Advancing Clinical Applications in Cancer Treatment. Journal of Clinical Medicine. 2024;13(21):6537. doi:10.3390/jcm13216537
BibTeX
@article{Garg2024,
author = {Garg, Pankaj and Pareek, Siddhika and Kulkarni, Prakash and Horne, David and Salgia, Ravi and Singhal, Sharad S},
title = {Next-Generation Immunotherapy: Advancing Clinical Applications in Cancer Treatment},
journal = {Journal of Clinical Medicine},
year = {2024},
volume = {13},
number = {21},
pages = {6537},
doi = {10.3390/jcm13216537}
}
EUVIMED